A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer

Date de début de l'étude : 1 juin 2000

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced unresectable, locally recurrent, or metastatic renal cell carcinoma not eligible for a higher priority trial Measurable disease Longest diameter at least 20 mm with conventional techniques or at least 10 mm with spiral CT scan No nonmeasurable disease only including: Bone lesions Leptomeningeal disease Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Abdominal masses not confirmed and followed by imaging techniques Cystic lesions No known brain metastases History of brain metastases that have been resected and/or irradiated with subsequent normal brain CT scan allowed PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 OR Karnofsky 60-100% Life expectancy: Greater than 12 weeks Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin no greater than 1.5 mg/dL AST/ALT no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia Other: Not pregnant or nursing Fertile patients must use effective contraception No other prior malignancy within the past 2 years except nonmelanoma skin cancer or carcinoma in situ of any site No history of allergic reactions attributed to compounds of similar chemical or biologic composition to rebeccamycin analogue No other concurrent uncontrolled illness (e.g., ongoing or active infection) No concurrent psychiatric illness or social situation that would preclude study compliance HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed Recovered from toxic effects Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered Surgery: See Disease Characteristics Other: No other concurrent investigational or commercial agents or therapies for renal cell cancer